Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic dissemination
Tarek Taifour, Adéline Massé, Yu Gu, Virginie Sanguin-Gendreau, Dongmei Zuo, Bin Xiao, Emilie Solymoss, Yunyun Shen, Hailey Proud, Sherif Samer Attalla, Vasilios Papavasiliou, Nancy U. Lin, Melissa E. Hughes, Kalie Smith, Chun Geun Lee, Suchitra Kamle, Josie Ursini-Siegel, Jack A. Elias, Peter M. Siegel, Rinath Jeselsohn, William J. Muller
Tarek Taifour, Adéline Massé, Yu Gu, Virginie Sanguin-Gendreau, Dongmei Zuo, Bin Xiao, Emilie Solymoss, Yunyun Shen, Hailey Proud, Sherif Samer Attalla, Vasilios Papavasiliou, Nancy U. Lin, Melissa E. Hughes, Kalie Smith, Chun Geun Lee, Suchitra Kamle, Josie Ursini-Siegel, Jack A. Elias, Peter M. Siegel, Rinath Jeselsohn, William J. Muller
View: Text | PDF
Research Article Immunology Oncology

The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic dissemination

  • Text
  • PDF
Abstract

Immunosuppression and metastasis are critical hallmarks of breast cancer, often linked to poor patient outcomes. The secreted cytokine chitinase-3–like 1 (CHI3L1) is frequently overexpressed in breast cancer samples and promotes an immunosuppressed tumor microenvironment. Notably, CHI3L1 expression is elevated in metastatic patient samples when compared with the matched primary breast tumor. To investigate its role in breast cancer metastasis, we generated an inducible genetically engineered mouse model that overexpresses CHI3L1 in the mammary epithelium. Ectopic expression of CHI3L1 in the polyomavirus middle T (PyMT) mouse model of breast cancer suppressed antitumor immune responses, accelerated mammary tumor onset, and enhanced lung metastasis. Mechanistically, elevated CHI3L1 expression in the mammary epithelium enhanced neutrophil recruitment, which subsequently degraded the extracellular matrix and increased the number of circulating tumor cells. These findings reveal a key mechanism driving metastatic dissemination and argue that therapeutically targeting Chi3l1 could enhance antitumor immunity and suppress metastasis.

Authors

Tarek Taifour, Adéline Massé, Yu Gu, Virginie Sanguin-Gendreau, Dongmei Zuo, Bin Xiao, Emilie Solymoss, Yunyun Shen, Hailey Proud, Sherif Samer Attalla, Vasilios Papavasiliou, Nancy U. Lin, Melissa E. Hughes, Kalie Smith, Chun Geun Lee, Suchitra Kamle, Josie Ursini-Siegel, Jack A. Elias, Peter M. Siegel, Rinath Jeselsohn, William J. Muller

×

Figure 5

Neutrophil degranulation and NETosis promote ECM remodeling.

Options: View larger image (or click on image) Download as PowerPoint
Neutrophil degranulation and NETosis promote ECM remodeling.
(A) Represe...
(A) Representative images of ECM-invading PyMT+ cells with control medium or neutrophil-conditioned medium (Neutrophil CM) treated with vehicle, Nex20, or Pad4i, stained with crystal violet. (B) Quantification of invading PyMT+ cells (n = 3 technical replicates) in A. (C) H&E staining of mammary glands from vehicle-, Pad4i-, or Nex20-treated MIC Chi3l1 OE mice at 2 weeks after induction. (D) Quantification of hyperplastic area in vehicle-treated (n = 8), Pad4i-treated (n = 8), and Nex20-treated (n = 8) MIC Chi3l1 OE mice at 2 weeks after induction. Represented as percentage of total mammary gland area. (E and F) Quantification of area occupied by laminin or collagen IV in Pad4i-treated (n = 8), Nex20-treated (n = 8), or vehicle-treated (n = 8) MIC Chi3l1 OE mammary glands at 2 weeks after induction. Represented as percentage of total mammary gland area. (G) Staining of mammary tissue from MIC Chi3l1 OE mice treated with Pad4i, Nex20, or vehicle control for 2 weeks, using antibodies against laminin, collagen IV, pan-CK, and DAPI. (H) Representative H&E staining of Chi3l1 OE MIC lungs treated with Pad4i, Nex20, or vehicle control for 6 weeks. (I) Percentage of Chi3l1 OE MIC mice with pulmonary metastases after treatment with Pad4i, Nex20, or vehicle control for 6 weeks. (J) Quantification of total pulmonary metastatic area in Chi3l1 OE MIC lungs after treatment with Pad4i (n = 4), Nex20 (n = 4), or vehicle control (n = 4) for 6 weeks. Represented as percentage of total lung area. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by 1-way ANOVA with Dunnett’s post hoc test. Scale bars: 100 μm in A and C; 10 μm in G; 1 mm in H, left panels; 100 μm in H, right panels.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts